Skip to main content
Monte Rosa Therapeutics, Inc. logo

Monte Rosa Therapeutics, Inc. — Investor Relations & Filings

Ticker · GLUE ISIN · US61225M1027 US Manufacturing
Filings indexed 324 across all filing types
Latest filing 2023-02-14 Major Shareholding Noti…
Country US United States of America
Listing US GLUE

About Monte Rosa Therapeutics, Inc.

https://www.monterosatx.com/

Monte Rosa Therapeutics is a clinical-stage biotechnology company that develops small molecule precision medicines known as molecular glue degraders (MGDs). The company's proprietary drug discovery platform is engineered to rationally design MGDs that leverage the body's natural protein disposal system to selectively eliminate disease-causing proteins. This approach targets proteins that have been historically considered "undruggable" or are inadequately addressed by existing therapies. By integrating expertise in chemistry, artificial intelligence, structural biology, and proteomics, Monte Rosa is advancing a pipeline of therapeutic candidates primarily for cancer and other serious diseases.

Recent filings

Filing Released Lang Actions
MONTE ROSA THERAPEUTICS, INC.
Major Shareholding Notification
2023-02-14 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-02-09 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-02-03 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated January 9, 2023. It includes a Regulation FD Disclosure about a press release and a presentation related to the company's participation at the 41st Annual J.P. Morgan Healthcare Conference. The document explicitly states that the press release and presentation are furnished as exhibits to this Form 8-K. There are no detailed financial statements or substantive financial data within the text itself, only references to the press release and presentation. The document length is 3881 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, such a document that announces or furnishes presentations and press releases related to an investor event should be classified as an Investor Presentation (IP).
2023-01-09 English
FORM 4 SUBMISSION
Director's Dealing
2023-01-04 English
FORM 4 SUBMISSION
Director's Dealing
2023-01-04 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.